A newly engineered peptide called IBP-CP24 has the potential to be further developed as a long-acting anti-HIV drug that can be used alone or in combination with a broad neutralizing antibody for the treatment and prevention of HIV-1 infection, according to a new study.
source https://www.sciencedaily.com/releases/2019/12/191205141756.htm
source https://www.sciencedaily.com/releases/2019/12/191205141756.htm
Comments
Post a Comment